Baseline genotypic analysis of treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV)

被引：0
|
作者：
Miller, MD
Margot, NA
Waters, JM
Harris, J
Lu, B
Cheng, AK
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Gilead Sci Inc, Durham, NC USA
来源：
ANTIVIRAL THERAPY | 2004年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：U118 / U118
页数：1
相关论文
共 17 条
  • [1] Resistance analyses of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF (TDF) or Stavudine (d4T) with lamivudine (3TC) and efavirenz (EFV)
    McColl, DJ
    Margot, NA
    Tran, S
    Coakley, DF
    Cheng, AK
    Miller, MD
    ANTIVIRAL RESEARCH, 2003, 57 (03) : A40 - A40
  • [2] Substitution of zidovudine (AZT) for stavudine (D4T) in a regimen with lamivudine (3TC) and efavirenz (EFV)
    Knechten, H
    Stürner, KH
    Höhn, C
    Braun, P
    AIDS, 2000, 14 : S57 - S57
  • [3] THE SAFETY AND EFFICACY OF TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAIVE PATIENTS THROUGH SEVEN YEARS
    Carlevari, M.
    Cassetti, I.
    Madruga, J. V. R.
    Etzel, A.
    Suleiman, J.
    Zhou, Y.
    Cheng, A. K.
    Enejosa, J.
    INFECTION, 2009, 37 : 59 - 59
  • [4] The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients
    Cassetti, I.
    Madruga, J. V. R.
    Suleiman, J. M. A. H.
    Zhong, L.
    Enejosa, J.
    Cheng, A. K.
    ANTIVIRAL THERAPY, 2006, 11 (07) : L50 - L51
  • [5] Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) resulted in continued virological suppression and improvement in lipoatrophy through 2 years in HIV-infected patients
    Madruga, J. V. R.
    Cassetti, I.
    Suleiman, J. M. A. H.
    Zhong, L.
    Enejosa, J.
    Cheng, A. K.
    ANTIVIRAL THERAPY, 2006, 11 (07) : L21 - L21
  • [6] Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from study 903E
    Zhong, L
    Cotton, G
    Enejosa, J
    Cheng, AK
    ANTIVIRAL THERAPY, 2005, 10 (08) : L40 - L40
  • [7] COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO
    Rizzoli-Cordoba, A.
    Delgado-Ginebra, I
    Pizarro-Castellanos, M.
    Castillo, J. J.
    VALUE IN HEALTH, 2011, 14 (03) : A119 - A119
  • [8] Economic comparison of lopinavir/r versus nelfinavir in combination with 3Tc and d4T in ARV-naive patients
    Simpson, KN
    Voit, EO
    Goodman, R
    Ashraf, T
    Hutton, J
    Sun, E
    AIDS, 2000, 14 : S103 - S103
  • [9] Safety and efficacy of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in treatment-naive HIV-1 infected adults with transmitted NNRTI resistance mutations
    Wong, A.
    Goldstein, D.
    Mallolas, J.
    DeJesus, E.
    Johnson, M.
    Molina, J.
    Pozniak, A.
    Rodgers, A.
    Teal, V.
    Hepler, D.
    Kumar, S.
    Sklar, P.
    Hanna, G.
    Hwang, C.
    Badshah, C.
    Teppler, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [10] Improvement in dyslipidaemias among patients receiving HAART after substitution of tenofovir DF (TDF) for stavudine (d4T) with or without use of a concomittant lipid lowering agent (LLA)
    Gilmore, J
    Guyer, B
    Barbour, C
    ANTIVIRAL THERAPY, 2004, 9 (06) : L58 - L59
12